Skip to main content
Home

Top menu InfoLep

  • About InfoLep
  • News & Events
  • e-learning.infoNTD.org
Home

Main navigation InfoLep

  • Leprosy [5]
    • Global and Regional Leprosy Situation
    • WHO Global Leprosy Strategy
    • ILEP Strategy
    • World Leprosy Day
    • Leprosy journals
  • Key topics [7]
    • Leprosy and COVID-19
    • Diagnostic tests
    • Prevention of leprosy [2]
      • Interventions to reduce transmission: post-exposure prophylaxis (PEP) [3]
        • LPEP Programme
        • PEP++ project
        • PEP4LEP project
      • Interventions to reduce transmission: vaccines
    • Rehabilitation & prevention of disability [2]
      • Preventing leprosy-related disabilities in girls and boys
      • Self-care in leprosy
    • Leprosy Antibiotic Treatment
    • Stigma, discrimination & mental wellbeing [4]
      • World Leprosy Day 2022
      • Gender
      • Mental wellbeing
      • SARI Project
    • Bioarchaeology of leprosy
  • Toolkits [6]
    • Guides on Stigma and Mental Wellbeing [5]
      • Guide 1. What are health-related stigma and mental wellbeing? [8]
        • 1. What is stigma?
        • 2. Why does stigma exist?
        • 3. What are the causes of stigma?
        • 4. Who stigmatises?
        • 5. How does it feel to experience stigma?
        • 6. What are the effects of stigma?
        • 7. Effects of stigma and discrimination on mental wellbeing
        • Annex Guide 1
      • Guide 2. How to reduce the impact of stigma [7]
        • 1. From undetected disease to diagnosis to support
        • 2. Individual-level interventions
        • 3. Group-level interventions
        • 4. Family-level interventions
        • 5. Referral
        • 6. Further reading
        • Annexes Guide 2
      • Guide 3. How to reduce sources of stigma [6]
        • 1. Background to the design of a stigma-reduction intervention
        • 2. Identifying the sources of stigma
        • 3. Targeting an intervention
        • 4. Inclusion of affected persons and champions in interventions
        • 5. Interventions by source type
        • Annexes Guide 3
      • Guide 4. How to assess health-related stigma and mental wellbeing [9]
        • 1. What is the purpose of the assessment?
        • 2. What approach would best fit your purpose and context?
        • 3. Quantitative assessment methods
        • 4. Qualitative assessment methods
        • 5. Assessments using mixed methods
        • 6. Developing qualitative methods from scratch
        • 7. How do you conduct a stigma assessment?
        • 8. How to interpret and report your findings
        • Annexes Guide 4
      • Glossary
    • NTD Morbidity and Disability Toolkit [15]
      • CHIEF
      • Clinical Profile
      • EMIC affected persons
      • EMIC-CS Community Stigma
      • Participation Scale
      • Patient Health Questionnaire (PHQ-9)
      • 5-Question Stigma Indicators
      • Salsa Scale
      • SARI Stigma Scale
      • SDS Social Distance Scale
      • SRQ Self-reporting Questionnaire
      • Warwick-Edinburgh Mental Wellbeing Scale (WEMWBS)
      • WGQ Washington Group Questions
      • WHODAS
      • WHOQOL-BREF
    • Perception Study Toolkit (PST)
    • Zero Leprosy Toolkit
    • CBM's Community Mental Health Good Practice Guides
    • GPZL & Infolep Factsheets
  • Online courses

Top menu InfoLep

  • About InfoLep
  • News & Events
  • e-learning.infoNTD.org
Visit our e-learning platform
Search resources Search in Practical Materials, Publications, Organizations, Online Course and more
Publication

Hypertensive Crisis and Myocardial Infarction With Non-obstructive Coronary Arteries in a Leprosy Patient With Erythema Nodosum Leprosum: The Role of Corticosteroids

Rathod N, Toshniwal SS, Chavhan R, et al. Springer Science and Business Media LLC. Cureus. 2025;
Download PDF
Publication

Exploring the Potential Use of Withania somnifera in Leprosy and Lepra Reactions: A Molecular Docking Approach.

Thangaraju P, Saraswathy T, Velmurugan H, et al. Infectious disorders drug targets. 2024;
Publication

Protective effects of BCG vaccination against multibacillary disease, reactions, and disabilities in childhood leprosy: Insights from a retrospective observational study from a tertiary care center in India

Narang T, Sharma A, Kaushal I, et al. Wiley. International Journal of Dermatology. 2025;
Publication

Tofacitinib in Leprosy: A Novel Therapeutic Approach in Chronic Recalcitrant Type II Reactions.

Suresh B, Reshmi P, Jaipal J, et al. Cureus. 2024; 16 (11) : 1-5.
Download PDF
Publication

A Retrospective Hospital Based Study on Deformities in Leprosy Patients in Leprosy Elimination and Post Covid Era in Southern India

Spandana K, Shetty U, Aishwarya R, et al. Indian Journal of Leprosy. 2024;
Download PDF
Publication

Survey on Awareness among Physiotherapists for Prevention and Management of Disabilities in Patients with Leprosy

Shetty M, Bagwe H, Patil S, et al. Indian Journal of Leprosy. 2024;
Download PDF
Publication

Leprosy and Lupus: Concurrence or Epiphenomenon

Parekh A, Shah H, Chavda A. Indian Journal of Leprosy. 2024;
Download PDF
Publication

Hansen’s Disease Mimicking as Papulosquamous Conditions – A Case Series

Gaikwad P, Gadkar S, Agrawal A, et al. Indian Journal of Leprosy. 2024;
Download PDF
Publication

Rare Presentation of Type 2 Lepra Reaction with Suppurative Lymphadenitis and Pustular Sweets Syndrome-like Lesions

Chauhan S, Verma G, Negi L, et al. Indian Journal of Leprosy. 2024;
Download PDF
Publication

Cutaneous Sarcoidosis Treated as Leprosy- A Case Report

Patil R, Marfatia Y, Patel B. Indian Journal of Leprosy. 2024;
Download PDF

Pagination

  • Previous page ‹‹
  • Page 4
  • Next page ››
Subscribe to India

Quick links

  • Leprosy
  • Key topics
  • Toolbox
  • Publications

Support

  • Contact
  • Privacy statement
  • Contact
  • FAQ

Contact us

info@infolep.org

(+31) 20 595 0500

     

Stay up to date with the latest publications and news related to leprosy.

Subscribe to newsletter

Related websites:

  • infontd

© 2025 InfoNTD